Truffle Capital reports outstanding 2020 stock market performance for its listed BioMedTech portfolio companies
Ranking among the best 2020 stock performers listed on Euronext Paris
- THREE LEADING BIOMEDTECH COMPANIES, FOUNDED OR CO-FOUNDED AND SUPPORTED BY TRUFFLE CAPITAL SINCE THEIR INCEPTION, GENERATE OUSTANDING PERFORMANCE IN 2020
As of today, Abivax (EPA: ABVX), Carbios (EPA: ALCRB) and Carmat (EPA: ALCAR), are collectively capitalizing €1.3 billion (497, 443 and 379 M€ respectively) and ranking among the best 2020 stock performers listed on Euronext Paris (including Carbios at the 1st position; among the companies capitalizing between €200 million and 2 billion; see table below). These three companies are all developing radical innovations aiming at revolutionizing the medical sector or the protection of the environment.
Here are the latest companies’ breaking news for these three companies:
• November 19, 2020: Carbios, founded by Truffle Capital in 2011 develops industrial bioprocesses for the circular economy of plastics, Carbios made its first 100% recycled plastic bottle from textiles. Based in French region of Auvergne, Carbios published a major scientific article in Nature, was able to attract renowned corporate partners (L’Oréal, Michelin, Nestlé Waters, Novozymes, PepsiCo, Suntory Beverage & Food Europe), and is now at the industrial pilot stage. Link: News/Carbios/First Plastic Bottle from Recycled Textile Link: News/Carbios/Nature Cover Page
• December 22, 2020: Abivax, founded by Truffle Capital in 2013, is developing innovative drugs to treat patients with inflammatory diseases, viral diseases and cancers. Abivax ABX464 drug candidate was declared a National Covid-19 Research Priority by the French government for its large international clinical trial, miR-AGE, launched last May with ABX464. This BioTech company already secured €84 million in funding over the year. Link: News/Abivax/National Covid-19 Research Priority
• December 23, 2020: Carmat, co-founded by Truffle Capital, Airbus and Pr Carpentier in 2008, designer and developer of the world's most advanced total artificial heart conceived to provide a therapeutic alternative for patients suffering from end-stage biventricular heart failure, obtained market approval in Europe (CE marking).
Link: News/Carmat/CE Marking
For detailed information regarding these companies, including risk factors, please refer to their respective websites (Carbios: www.carbios.fr; Abivax: www.abivax.com and Carmat: www.carmatsa.com).
Full PR attached
